IL6 and myocardial infarction: Specifically, in the Anti-IL-6 treatment in Myocardial Infarction (ASSAIL-MI) trial, a single infusion of tocilizumab was shown to increase myocardial salvage (as measured by magnetic resonance imaging) in patients with ST-segment elevation myocardial infarction compared to placebo [38].